{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Riluzole+%28100+mg%29", "query": { "intervention": "Riluzole (100 mg)" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-28T07:00:50.729Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06552260", "title": "A Surgical Window of Opportunity Clinical Trial of Troriluzole in Recurrent IDH Wild-Type Glioblastoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Glioblastoma", "Recurrent Glioblastoma", "Brain Tumor" ], "interventions": [ { "name": "Troriluzole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ugonma Chukwueke", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2025-02-19", "completion_date": "2027-08-01", "has_results": false, "last_update_posted_date": "2025-09-11", "last_synced_at": "2026-09-28T07:00:50.729Z", "location_count": 3, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06552260" }, { "nct_id": "NCT00419003", "title": "Research Study for Major Depressive Disorder: Investigation of Glutamate Medications", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Major Depression" ], "interventions": [ { "name": "Lamotrigine", "type": "DRUG" }, { "name": "Ketamine", "type": "DRUG" }, { "name": "Riluzole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Baylor College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "21 Years to 70 Years" }, "enrollment_count": 26, "start_date": "2006-12", "completion_date": "2008-09", "has_results": true, "last_update_posted_date": "2019-07-31", "last_synced_at": "2026-09-28T07:00:50.729Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00419003" }, { "nct_id": "NCT07142291", "title": "PHENOGENE-1A (Cromolyn) Treatment in Patients With Mild to Moderate ALS", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Amyotrophic Lateral Sclerosis (ALS)" ], "interventions": [ { "name": "Cromolyn Sodium (34.2 mg BID)", "type": "DRUG" }, { "name": "Cromolyn Sodium (17.1 mg BID)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Riluzole (100 mg)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "PhenoNet, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 105, "start_date": "2025-11-25", "completion_date": "2027-06", "has_results": false, "last_update_posted_date": "2026-07-23", "last_synced_at": "2026-09-28T07:00:50.729Z", "location_count": 5, "location_summary": "Scottsdale, Arizona • La Jolla, California • San Francisco, California + 2 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07142291" }, { "nct_id": "NCT02796755", "title": "Effects of Riluzole on CNS Glutamate and Fatigue in Breast Cancer Survivors With High Inflammation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Inflammation", "Fatigue" ], "interventions": [ { "name": "Riluzole", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": "65 Years", "sex": "FEMALE", "summary": "21 Years to 65 Years · Female only" }, "enrollment_count": 30, "start_date": "2016-04", "completion_date": "2019-10-24", "has_results": true, "last_update_posted_date": "2021-04-14", "last_synced_at": "2026-09-28T07:00:50.729Z", "location_count": 1, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02796755" }, { "nct_id": "NCT04630444", "title": "Riluzole Effects on Hippocampus Biomarkers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Posttraumatic Stress Disorder" ], "interventions": [ { "name": "Riluzole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mclean Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 20, "start_date": "2017-03-16", "completion_date": "2019-03-16", "has_results": false, "last_update_posted_date": "2020-11-16", "last_synced_at": "2026-09-28T07:00:50.729Z", "location_count": 1, "location_summary": "Belmont, Massachusetts", "locations": [ { "city": "Belmont", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04630444" }, { "nct_id": "NCT00544544", "title": "Riluzole in the Treatment of Bipolar Depression", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Bipolar Depression" ], "interventions": [ { "name": "Riluzole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mclean Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 14, "start_date": "2007-06", "completion_date": "2009-07", "has_results": true, "last_update_posted_date": "2018-08-07", "last_synced_at": "2026-09-28T07:00:50.729Z", "location_count": 1, "location_summary": "Belmont, Massachusetts", "locations": [ { "city": "Belmont", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00544544" }, { "nct_id": "NCT00376220", "title": "A Double-Blind Placebo Controlled Trial of Riluzole in Bipolar Depression", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bipolar Disorder" ], "interventions": [ { "name": "Riluzole", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Johns Hopkins University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 94, "start_date": "2004-05", "completion_date": "2010-05", "has_results": true, "last_update_posted_date": "2017-04-11", "last_synced_at": "2026-09-28T07:00:50.729Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00376220" }, { "nct_id": "NCT01703039", "title": "Riluzole Augmentation Pilot in Depression (RAPID) Trial", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Major Depressive Disorder" ], "interventions": [ { "name": "Riluzole", "type": "DRUG" }, { "name": "Sertraline", "type": "DRUG" }, { "name": "placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Brigham and Women's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 21, "start_date": "2013-01", "completion_date": "2018-06", "has_results": true, "last_update_posted_date": "2019-08-28", "last_synced_at": "2026-09-28T07:00:50.729Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01703039" }, { "nct_id": "NCT00866840", "title": "Riluzole in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma (Skin)" ], "interventions": [ { "name": "riluzole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rutgers, The State University of New Jersey", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 13, "start_date": "2009-04", "completion_date": "2013-07", "has_results": true, "last_update_posted_date": "2024-01-19", "last_synced_at": "2026-09-28T07:00:50.729Z", "location_count": 1, "location_summary": "New Brunswick, New Jersey", "locations": [ { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00866840" }, { "nct_id": "NCT02155829", "title": "Safety Study of Riluzole to Treat Post-traumatic Stress Disorder (PTSD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "PTSD" ], "interventions": [ { "name": "Riluzole", "type": "DRUG" }, { "name": "Placebo (for Riluzole)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Uniformed Services University of the Health Sciences", "sponsor_class": "FED", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 75, "start_date": "2013-07", "completion_date": "2017-11-30", "has_results": true, "last_update_posted_date": "2021-05-24", "last_synced_at": "2026-09-28T07:00:50.729Z", "location_count": 2, "location_summary": "Bethesda, Maryland • Syracuse, New York", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Syracuse", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02155829" } ] }